» Articles » PMID: 18688259

Methotrexate: an Option for Preventing the Recurrence of Acute Anterior Uveitis

Overview
Journal Eye (Lond)
Specialty Ophthalmology
Date 2008 Aug 9
PMID 18688259
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: To evaluate the efficacy of methotrexate (MTX) in preventing the recurrence of acute anterior uveitis (AAU).

Methods: This prospective, open, longitudinal study included patients from June 2002 to March 2005 who had either three or more episodes of AAU in the previous year, or a recurrence of AAU within 3 months before starting the trial. We excluded uveitis of infectious origin, masquerade syndromes, and patients with contraindications to MTX. The response criteria were defined as an absence of symptoms and the presence of a normal ophthalmologic examination. The study outcome compared the number of flare-ups of uveitis over an MTX-treated for 1 year to the number of flare-ups of the same group during the previous year without MTX.

Results: A total of 571 patients with uveitis were evaluated during the period of the study, and 10 fulfilled the inclusion criteria. One patient refused the treatment, and nine completed the study. The mean number of recurrences in the pre-MTX year was 3.4 (SD: 0.52), which was significantly reduced to 0.89 (SD: 1.17) in the year of treatment (P=0.011).

Conclusion: MTX treatment seems to reduce the number of flare-ups in patients with recurrent AAU.

Citing Articles

An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis.

Esteban-Ortega M, Steiner M, Andreu-Vazquez C, Thuissard-Vasallo I, Diaz-Rato A, Munoz-Fernandez S J Clin Med. 2024; 13(5).

PMID: 38592203 PMC: 10933845. DOI: 10.3390/jcm13051402.


[Non-infectious anterior uveitis : S1 guideline of the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). Version: 13.12.2023].

Ophthalmologie. 2024; 122(Suppl 1):1-12.

PMID: 38438812 DOI: 10.1007/s00347-024-02007-7.


Clinical characterization of patients with HLA-B27-associated uveitis and evaluation of the impact of systemic treatment on the recurrence rate: a cross-sectional study.

Pineda-Sierra J, Cifuentes-Gonzalez C, Rojas-Carabali W, Munoz-Vargas P, Henao-Posada A, de-la-Torre A J Ophthalmic Inflamm Infect. 2023; 13(1):38.

PMID: 37646883 PMC: 10468442. DOI: 10.1186/s12348-023-00352-3.


Pathogenesis and current therapies for non-infectious uveitis.

Wu X, Tao M, Zhu L, Zhang T, Zhang M Clin Exp Med. 2022; 23(4):1089-1106.

PMID: 36422739 PMC: 10390404. DOI: 10.1007/s10238-022-00954-6.


Pharmacokinetics and Toxicity Evaluation of a PLGA and Chitosan-Based Micro-Implant for Sustained Release of Methotrexate in Rabbit Vitreous.

Manna S, Donnell A, Faraj R, Riemann B, Riemann C, Augsburger J Pharmaceutics. 2021; 13(8).

PMID: 34452188 PMC: 8398642. DOI: 10.3390/pharmaceutics13081227.